The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat-Reference-Cited by-同舟云学术

The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat

Published:2014-07-03 Issue:3 Volume:350 Page:657-664
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Hansen Henrik H.,Jelsing Jacob,Hansen Carl Frederik,Hansen Gitte,Vrang Niels,Mark Michael,Klein Thomas,Mayoux Eric

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference33 articles.

1. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+ -glucose cotransporter inhibitor T-1095

2. Renal glucose reabsorption inhibitors to treat diabetes

3. Effects of sulfonylureas, α-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes

4. Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARα/γ agonist on glycaemic control in Zucker diabetic fatty rats

5. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are sodium‐glucose cotransporter‐2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation;Journal of Diabetes;2024-06-26

2. Pioglitazone/Exenatide/SGLT-2 inhibitor combination therapy versus insulin therapy in patients with poorly controlled type 2 diabetes;Anatolian Current Medical Journal;2024-03-08

3. Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes;Basic & Clinical Pharmacology & Toxicology;2024-02-26

4. Pharmacological inhibitors of β-cell dysfunction and death as therapeutics for diabetes;Frontiers in Endocrinology;2023-03-15

5. The Metabolic Syndrome and Vascular Disease;Diabetes and Cardiovascular Disease;2023